Trends of insulin pump therapy and continuous glucose monitoring use among people with type 1 diabetes by institution and region in Japan during 2014 and 2022: an observational study using nationwide claims data
Authors' conclusion
In Japan, use of insulin pumps and CGM increased from 2014 to 2022, but pump uptake remained modest with persistent facility and prefecture variation.
Study context
- Population
- Individuals with T1D receiving regular care, Japan's National Database of Health Insurance Claims (FY2014–2022)91,260 in FY2014
- Outcome
- Annual use of insulin pumps, sensor-augmented pumps (SAP) and CGM
- Follow-up
- FY2014–2022
Methodological detailsnationwide claims data, observational
- Nationwide claims data
- Observational
Main finding
As reported in the abstract
Use of diabetes technology · FY2014 to FY2022
Insulin pump use, FY2014 to FY2022
5.9% to 9.7%
Sensor-augmented pumps (SAP) use, FY2014 to FY2022
0.2% to 4.3%
Continuous glucose monitoring (CGM) use, FY2014 to FY2022
0.2% to 39.8%
Observational data: associations, not effects.
Further findings
- Uptake higher in high-volume and certified facilities
- Geographic variation persisted; prefecture-level uptake more closely associated with broader facility adoption than concentration of care
Original publication
Trends of insulin pump therapy and continuous glucose monitoring use among people with type 1 diabetes by institution and region in Japan during 2014 and 2022: an observational study using nationwide claims data. Diabetes Res Clin Pract. Published 27 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →